Wednesday, 25 April 2012

Animal Health Products-Quarterly Profit-Strong Sales

Lilly sales, profit beat forecasts

(Reuters) - Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products. The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges. Excluding special items, Lilly earned 92 cents per share. ... read more..

No comments:

Post a Comment